You are here

GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 261201600034C-3-0-0
Agency Tracking Number: N43CA160034
Amount: $1,915,127.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: N/A
Timeline
Solicitation Year: 2017
Award Year: 2017
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
810 WYMAN PARK DR
BALTIMORE, MD 21211-2840
United States
DUNS: 079670802
HUBZone Owned: Unavailable
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ISAAC KINDE
 (617) 388-6512
 ik@papgeneinc.com
Business Contact
 ISAAC KINDE
Phone: (617) 388-6512
Email: ik@papgeneinc.com
Research Institution
N/A
Abstract

This proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyze DNA from routinely collected urine samples with a massively parallel sequencing based assay and includes a unique processing technique that increases detection sensitivity

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government